ES2487465T1 - Poblaciones celulares que tienen actividad immunoreguladora, método para la preparación y usos - Google Patents
Poblaciones celulares que tienen actividad immunoreguladora, método para la preparación y usos Download PDFInfo
- Publication number
- ES2487465T1 ES2487465T1 ES12723442.5T ES12723442T ES2487465T1 ES 2487465 T1 ES2487465 T1 ES 2487465T1 ES 12723442 T ES12723442 T ES 12723442T ES 2487465 T1 ES2487465 T1 ES 2487465T1
- Authority
- ES
- Spain
- Prior art keywords
- cells
- cell population
- multiple sclerosis
- myelin
- population
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims 12
- 230000004957 immunoregulator effect Effects 0.000 title 1
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract 10
- 239000000427 antigen Substances 0.000 claims abstract 8
- 102000036639 antigens Human genes 0.000 claims abstract 8
- 108091007433 antigens Proteins 0.000 claims abstract 8
- 230000002519 immonomodulatory effect Effects 0.000 claims abstract 5
- 102100027581 Forkhead box protein P3 Human genes 0.000 claims abstract 3
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 claims abstract 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims abstract 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims 28
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 102000006386 Myelin Proteins Human genes 0.000 claims 3
- 108010083674 Myelin Proteins Proteins 0.000 claims 3
- 210000004248 oligodendroglia Anatomy 0.000 claims 3
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 claims 2
- 102100028682 Claudin-11 Human genes 0.000 claims 2
- 108050007280 Claudin-11 Proteins 0.000 claims 2
- 102000047918 Myelin Basic Human genes 0.000 claims 2
- 101710107068 Myelin basic protein Proteins 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 210000000265 leukocyte Anatomy 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 210000005012 myelin Anatomy 0.000 claims 2
- 210000003289 regulatory T cell Anatomy 0.000 claims 2
- 108090000288 Glycoproteins Proteins 0.000 claims 1
- 102000003886 Glycoproteins Human genes 0.000 claims 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims 1
- 101000622137 Homo sapiens P-selectin Proteins 0.000 claims 1
- 102000055324 Myelin Proteolipid Human genes 0.000 claims 1
- 101710094913 Myelin proteolipid protein Proteins 0.000 claims 1
- 108010013731 Myelin-Associated Glycoprotein Proteins 0.000 claims 1
- 102000017099 Myelin-Associated Glycoprotein Human genes 0.000 claims 1
- 102000002233 Myelin-Oligodendrocyte Glycoprotein Human genes 0.000 claims 1
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 claims 1
- 108010077641 Nogo Proteins Proteins 0.000 claims 1
- 102100023472 P-selectin Human genes 0.000 claims 1
- 102100035917 Peripheral myelin protein 22 Human genes 0.000 claims 1
- 101710199257 Peripheral myelin protein 22 Proteins 0.000 claims 1
- 108010010974 Proteolipids Proteins 0.000 claims 1
- 102000016202 Proteolipids Human genes 0.000 claims 1
- 102100029831 Reticulon-4 Human genes 0.000 claims 1
- 210000000577 adipose tissue Anatomy 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1352—Mesenchymal stem cells
- C12N2502/1382—Adipose-derived stem cells [ADSC], adipose stromal stem cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Una población celular aislada que consiste esencialmente en células inmunomoduladoras específicas de antígeno asociado a esclerosis múltiple que expresan uno o más de CD62-L, FOXP3 y CTLA4.
Claims (1)
- REIVINDICACIONES1.Una población celular aislada que consiste esencialmente en células inmunomoduladoras específicas de antígeno asociado a esclerosis múltiple que expresan uno o más de CD62-L, FOXP3 y CTLA4.52.La población celular según la reivindicación 1en donde dichas células expresan cada uno de CD62-L, FOXP3 y CTLA4.3.La población celular según la reivindicación 1 o 2 en donde dichas células no expresan CD127.104.La población celular según cualquiera de las reivindicaciones 1 a 3 en donde dichas célulasson células T reguladoras.5.La población celular según cualquiera de las reivindicaciones 1 a 4 en donde dichas células se generan ex vivoy se dirigen o exponen a uno o más antígenos durante dicha generación ex vivo.156.Un método para la preparación, expansión y/o generación de células inmunomoduladoras específicas de antígeno que comprende poner en contacto una célula T reguladora aislada o población celular de las mismas con una población de células madre mesenquimatosas (MSC) en presencia de uno o más antígenos asociados a esclerosis múltiple.207.Un método para la selección de una población celular que comprende:i)proporcionar una población celular aislada;ii)determinar la expresión de uno o más marcadores seleccionados del grupo que consiste en CD62-L, 25FOXP3y CTLA4; yiii)seleccionar células positivas para al menos 1, 2 o 3 de dichos marcadores.8.Un método para tratar a un sujeto que tiene esclerosis múltiple que comprende los pasos de:30i)proporcionar una población de PBL;ii)poner en contacto dichos PBL con una población celular que comprende células MSC y/o fibroblastos en presencia de uno o más antígenos asociados a esclerosis múltiple; iii)aislar la población de células inmunomoduladoras; yiv)administrar la población de células inmunomoduladoras a dicho sujeto.359.El método según la reivindicación 6 o 8 en donde la población de MSC deriva de tejido adiposo.10.La población celular según cualquiera de las reivindicaciones 1 a 5 o el método según cualquiera de las reivindicaciones 6, 8o 9 en donde dicho antígeno asociado a esclerosis múltiple se selecciona del grupo que 40consiste en proteína básica de la mielina, glicoproteína asociada a mielina, proteína de oligodendrocitos de mielina, proteína de proteolípido, oligoproteína de mielinade oligodendrocitos, proteína básica de oligodendrocitos asociada a mielina, proteína específica de oligodendrocitos, proteínas de choque térmico, proteínas específicas de oligodendrocitos, NOGO A, glicoproteína Po, proteína de mielina periférica 22, y 2’3’-nucleótido cíclico3’-fosfodiesterasa, y fragmentos, variantes y mezclas de las mismas.4511.El método según la reivindicación 10 en donde dichos antígenos asociados a esclerosis múltiple se seleccionan del grupo que comprende péptidos de proteína básica dela mielina, glicoproteínas de oligodendrocitos de mielina y proteínas de proteolípido y fragmentos, variantes y mezclas de los mismos.5012.Una composición farmacéutica que comprende las células según cualquiera de las reivindicaciones 1 a 5 o células preparadas según el método de cualquiera de las reivindicaciones 6, 9, 10 u 11.13.Una población celular según cualquiera de las reivindicaciones 1 a 5,células preparadas según el método de cualquiera de las reivindicaciones 6, 9, 10 u 11 o una composición farmacéutica según la reivindicación 12 55para su uso en el tratamiento de esclerosis múltiple.14.El uso de una población celular según cualquiera de las reivindicaciones 1 a 5,células preparadas según el método de cualquiera de las reivindicaciones 6, 9, 10 u 11 ouna composición farmacéutica según la reivindicación 12 en la fabricación de un medicamentopara el tratamiento de esclerosis múltiple.6015.Un método de tratamiento de esclerosis múltiple que compren de administrar a un sujeto en necesidad de ello una población celular según cualquiera de las reivindicaciones 1 a 5,células preparadas según el método de cualquiera de las reivindicaciones 6, 9, 10 u 11 o una composición farmacéutica según la reivindicación 12.65
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11166808 | 2011-05-19 | ||
| EP11166808 | 2011-05-19 | ||
| PCT/EP2012/059313 WO2012156522A1 (en) | 2011-05-19 | 2012-05-18 | Cell populations having immunoregulatory activity, methods for the preparation and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2487465T1 true ES2487465T1 (es) | 2014-08-20 |
Family
ID=46149436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12723442.5T Pending ES2487465T1 (es) | 2011-05-19 | 2012-05-18 | Poblaciones celulares que tienen actividad immunoreguladora, método para la preparación y usos |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20140348808A1 (es) |
| EP (1) | EP2710122B1 (es) |
| JP (2) | JP2014515258A (es) |
| KR (1) | KR20140071277A (es) |
| ES (1) | ES2487465T1 (es) |
| WO (1) | WO2012156522A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011056972A2 (en) | 2009-11-04 | 2011-05-12 | Case Western Reserve University | Compositions and methods of treating a t cell mediated disorder |
| FR2976580B1 (fr) * | 2011-06-14 | 2013-05-31 | Coatex Sas | Epaississants non ioniques associatifs contenant des alkyls cyclohexylols, formulations les contenant et leurs utilisations. |
| EP3551749B1 (en) | 2016-12-07 | 2023-09-27 | East Carolina University | Compositions and methods for in vitro cultivation and/or expansion of regulatory t cells |
| AU2019242381A1 (en) * | 2018-03-27 | 2020-11-19 | Aztherapies, Inc. | CAR-Treg-based therapies for treating neurodegenerative diseases |
| CN109913415B (zh) * | 2019-03-26 | 2020-05-22 | 广东先康达生物科技有限公司 | Treg细胞的培养液及其培养方法与应用 |
| AU2022337351A1 (en) * | 2021-09-03 | 2024-03-21 | Sangamo Therapeutics, Inc. | Mog-binding proteins and uses thereof |
| WO2024046355A1 (en) * | 2022-09-02 | 2024-03-07 | Medical And Pharmaceutical Industry Technology And Development Center | Use of composition including mesenchymal stem cells for alleviating myelofibrosis |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030147865A1 (en) * | 2002-02-07 | 2003-08-07 | Benoit Salomon | Cell therapy using immunoregulatory T-cells |
| CN1953767B (zh) * | 2004-01-08 | 2011-03-16 | 加利福尼亚大学董事会 | 调节t细胞抑制自身免疫 |
| EP1913387B1 (en) * | 2005-08-02 | 2016-01-20 | Centenary Institute of Cancer Medicine & Cell Biology | Method for identifying regulatory t cells |
| CA2953782C (en) | 2005-09-23 | 2023-09-12 | Centro Superior De Investigaciones Cientificas | Cell populations having immunoregulatory activity, method for isolation and uses |
| EP2050814A1 (en) * | 2007-10-17 | 2009-04-22 | Txcell | Compositions for treating multiple sclerosis |
| CN102459577B (zh) * | 2009-05-18 | 2014-08-20 | 特拉科斯有限公司 | 适合临床应用于免疫介导性疾病的、具有增强型抑制功能的调节性t细胞的体外扩增方法 |
| GB0918615D0 (en) * | 2009-10-23 | 2009-12-09 | Cellerix Sa | Cell populations having immunoregulatory activity, methods for the preparation and uses thereof |
-
2012
- 2012-05-18 KR KR1020137030844A patent/KR20140071277A/ko active Search and Examination
- 2012-05-18 JP JP2014510832A patent/JP2014515258A/ja active Pending
- 2012-05-18 WO PCT/EP2012/059313 patent/WO2012156522A1/en active Application Filing
- 2012-05-18 US US14/118,741 patent/US20140348808A1/en not_active Abandoned
- 2012-05-18 ES ES12723442.5T patent/ES2487465T1/es active Pending
- 2012-05-18 EP EP12723442.5A patent/EP2710122B1/en active Active
-
2018
- 2018-04-04 JP JP2018072015A patent/JP6592551B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2710122A1 (en) | 2014-03-26 |
| JP2018134086A (ja) | 2018-08-30 |
| KR20140071277A (ko) | 2014-06-11 |
| JP2014515258A (ja) | 2014-06-30 |
| WO2012156522A1 (en) | 2012-11-22 |
| EP2710122B1 (en) | 2021-03-31 |
| US20140348808A1 (en) | 2014-11-27 |
| JP6592551B2 (ja) | 2019-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2487465T1 (es) | Poblaciones celulares que tienen actividad immunoreguladora, método para la preparación y usos | |
| US20200306319A1 (en) | Methods for treating radiation or chemical injury | |
| US20220090008A1 (en) | Colony forming medium and use thereof | |
| ATE544848T1 (de) | Cokultur-lte (lymphoid tissue equivalent) für artifizielles immunsystem (ais) | |
| BR112018003031A2 (pt) | formulações clínicas | |
| ATE522600T1 (de) | Anti-tumor impfstoff aus normalen chemisch modifizierten cd4+ zellen | |
| WO2007108835A3 (en) | Automatable artificial immune system (ais) | |
| WO2008073635A3 (en) | Automatable artificial immune system (ais) | |
| BR112014008694A2 (pt) | moléculas de ácido nucleico policistrônico recombinante | |
| BR112012021267A2 (pt) | métodos para a preparação de melanócitos a partir de células tronco humanas pluripotentes. | |
| JP2014515258A5 (es) | ||
| Parvizi et al. | Development of recombinant collagen‐peptide‐based vehicles for delivery of adipose‐derived stromal cells | |
| Chen et al. | The application of umbilical cord‐derived MSCs in cardiovascular diseases | |
| Hovhannisyan et al. | The role of non-immune cell-derived extracellular vesicles in allergy | |
| US20190093081A1 (en) | Placenta-derived intermediate natural killer (pink) cells for treatment of glioblastoma | |
| AR125461A1 (es) | Células presentadoras de antígeno recombinante | |
| BR112021010804A2 (pt) | Métodos para expansão seletiva in vivo de populações de células t gama delta e composições das mesmas | |
| ITRM20100416A1 (it) | Isolamento di cellule staminali pluripotenti da liquido amniotico e loro uso nel trattamento o nella prevenzione di malattie autoimmuni . | |
| Zhang et al. | Immunosafety evaluation of a multilayer flat-plate bioartificial liver | |
| Frith | Fat Therapeutics: The Clinical Capacity of Adipose-Derived Stem Cells and Exosomes for Human Disease and Tissue Regeneration | |
| Qu et al. | Transplantation of bone marrow-derived mesenchymal stem cells facilitates epithelial repair and relieves the impairment of gastrointestinal function in a rat model of enteritis | |
| RU2013158429A (ru) | Способ индукции противоопухолевого цитотоксического иммунного ответа с помощью дендритных клеток, трансфицированных рнк опухолевых клеток, против клеток рака молочной железы | |
| Abramov et al. | Cells interactions and cells modifications via exosomes | |
| DE60008368D1 (de) | Aus ganzen zellen bestehender krebs-impfstoff, enthaltend ko-kultivierte maligne und nicht-maligne zellen | |
| CL2022001380A1 (es) | Células madre mesenquimales con propiedades terapéuticas mejoradas |